Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).

PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.

The trial will enrol 600 subjects with confirmed metastatic castrate-resistant prostate cancer. Credit: Korawat photo shoot / Shutterstock. The US Food and Drug Administration (FDA) and the European ...